National Research Corp. (NASDAQ:NRCIB) CEO Michael D. Hays sold 3,533 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $16.19, for a total value of $57,199.27. Following the transaction, the chief executive officer now owns 6,467,744 shares of the company’s stock, valued at $104,712,775.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

National Research Corp. (NASDAQ:NRCIB) traded up 1.6323% during midday trading on Wednesday, reaching $36.1811. The company’s stock had a trading volume of 236 shares. The firm has a 50-day moving average price of $33.92 and a 200 day moving average price of $35.16. The stock has a market capitalization of $876.34 million, a price-to-earnings ratio of 44.4485 and a beta of 0.28. National Research Corp. has a 52-week low of $31.36 and a 52-week high of $44.60.

National Research Corp. (NASDAQ:NRCIB) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $0.18 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.18. National Research Corp. had a net margin of 18.75% and a return on equity of 33.74%. Equities research analysts predict that National Research Corp. will post $0.82 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Friday, September 30th will be given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 5.31%. The ex-dividend date of this dividend is Wednesday, September 28th. National Research Corp.’s dividend payout ratio is 408.52%.

An institutional investor recently bought a new position in National Research Corp. stock. Willis Investment Counsel purchased a new stake in shares of National Research Corp. (NASDAQ:NRCIB) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 13,329 shares of the company’s stock, valued at approximately $442,000. Willis Investment Counsel owned approximately 0.06% of National Research Corp. as of its most recent filing with the SEC. 2.90% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research upgraded National Research Corp. from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Friday, August 12th.

National Research Corp. Company Profile

National Research Corp. is a business services company in the Health Care Services industry.

5 Day Chart for NASDAQ:NRCIB

Receive News & Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.